Worldwide Clinical Oncology Next Generation Sequencing (NGS) Industry Size: Insights, Growth Trends and Forecast

Report ID : 1303875 | Published : February 2025 | Study Period : 2023-2033 | Format : PDF + Excel

The market size of the Clinical Oncology Next Generation Sequencing (NGS) Industry is categorized based on Technology (Sequencing Platforms, Bioinformatics, Consumables) and Application (Clinical Diagnostics, Research, Drug Development) and End User (Hospitals, Laboratories, Pharmaceutical Companies, Academic Institutions) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

In 2023, the size of the Clinical Oncology Next Generation Sequencing (NGS) Industry was valued at $3.2 billion and is anticipated to reach $12.4 billion by 2033, expanding at a 14.5% CAGR between 2024 and 2033. The report encompasses multiple segments and provides an analysis of significant trends and factors impacting the market.

The growth of the Clinical Oncology NGS Market is expected to accelerate significantly with the advancement in genomic technologies as they continue to transform cancer diagnosis and treatment. Oncologists are able to analyze genetic alterations and mutations precisely, offering oncologists critical information to fine-tune treatments. As a result, this approach transforms patient outcomes and intervention strategies, making NGS an indispensable part of oncology practice today. 

Healthcare professionals and researchers increasingly turn to NGS to solve the complicates issues presented by tumor genomics being cancer therapy needs become more sophisticated and effective. Finally, the incorporation of NGS into clinical practice does not just speed up the rate at which discoveries are done in oncology, but also equips clinicians with the capacity to develop customized treatment approaches for each patient based on their genetic makeup. Therefore, Clinical Oncology NGS Market, like many other areas of healthcare, is undergoing increased investments, innovations, and cultivations in diverse healthcare regions.

Furthermore the continuous partnership of technology developers, pharmaceutical businesses and healthcare providers is creating an environment which encourages the growth of NGS applications in oncology. As the regulations change alongside reimbursement strategies for these advanced technologies, the market is bound to grow. This expansion will both increase the scope of clinical oncology and assist in the overarching aim of enhancing cancer care across the globe.

 

ATTRIBUTES	DETAILS
STUDY PERIOD	2023-2033
BASE YEAR	2023
FORECAST PERIOD	2024-2033
HISTORICAL PERIOD	2023-2024
UNIT	VALUE (USD BILLION)
KEY COMPANIES PROFILED	Illumina Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Invitae Corporation, Myriad Genetics Inc., GeneDx Inc., Foundation Medicine Inc., Guardant Health Inc.
SEGMENTS COVERED	By Technology - Sequencing Platforms, Bioinformatics, Consumables By Application - Clinical Diagnostics, Research, Drug Development By End User - Hospitals, Laboratories, Pharmaceutical Companies, Academic Institutions By Geography - North America, Europe, APAC, Middle East Asia & Rest of World.

---

Clinical Oncology Next Generation Sequencing (NGS) Industry Dynamics

The Clinical Oncology Next Generation Sequencing (NGS) Industry is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.

Market Drivers

1. Technological Advancements
2. Increasing Consumer Demand
3. Regulatory Support
4. Globalization

Market Restraints

1. High Operational Costs
2. Regulatory Challenges
3. Market Saturation

Market Opportunities

1. Emerging Markets
2. Product Innovation
3. Strategic Partnerships

Market Challenges

1. Technological Disruptions
2. Supply Chain Issues
3. Changing Consumer Preferences

---

Key Players in the Clinical Oncology Next Generation Sequencing (NGS) Industry

This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Qiagen N.V.
• Agilent Technologies Inc.
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Invitae Corporation
• Myriad Genetics Inc.
• GeneDx Inc.
• Foundation Medicine Inc.
• Guardant Health Inc.

---

Customization Options

Verified Industry Insights offers one of the following report customization options to our respectable clients :

Company Profiling

● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)

Competitive Benchmarking

● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research

Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439

© 2024 Verified Industry Insights. All Rights Reserved